Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Poll Shows Incidence, Adverse Effects of Cancer-Related Fatigue

March 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

NEW YORK--A nationwide survey of US cancer patients, oncologists, and caregivers documents that fatigue has profound effects on patients, including their ability to work, meet family needs, and cope with the disease.

NEW YORK--A nationwide survey of US cancer patients, oncologists, andcaregivers documents that fatigue has profound effects on patients, includingtheir ability to work, meet family needs, and cope with the disease.

The survey, of 419 patients, 197 oncol-ogists, and 200 caregivers, showedthat 78% of cancer patients experience fatigue during the course of theirdisease, with 53% saying they experience fatigue on most days, if not everyday (Figure 1).

While 80% of physicians surveyed said they believe that fatigue is overlookedand undertreated, less than half reported that they discuss it with patientsor attempt to treat it.

"For many patients, fatigue is a daily reminder that they havecancer," said Nicholas Vogelzang, MD, professor of medicine, Universityof Chicago, and one of the authors of the survey. "If we can controlor lessen its effects, we go a long way toward restoring a sense of normalcyto patients' lives."

Some Too Tired to Eat

The survey was conducted by the research organization Wirthlin Worldwidefor The Fatigue Coalition, a multidiscipli-nary group of physicians andpatient advocates from institutions including Harvard, Stanford, MemorialSloan-Kettering, the University of Chicago, and the National Coalitionfor Cancer Survi-vorship. It was underwritten by Ortho Biotech Inc.

The majority of cancer patients reported that fatigue adversely affectstheir ability to work (61%) and interferes with their usual activities(51%), while 42% said that it negatively impacts their ability to takecare of their families (see Figure 2).For some, fatigue makes it difficult even to get out of bed (29%) or toeat their meals (24%).

Psychologically, fatigue also takes a tremendous toll: 57% of patientsin the study said they are unable to enjoy life fully because of fatigue,and 31% said that fatigue affects their hope of successfully fighting theircancer. Some 16% of patients surveyed said that treating their fatiguewas as important as treating the cancer itself, a "small althoughrelevant figure," Dr. Vogelzang said.

Other intriguing findings: While physicians believe that pain is moredebilitating and prevalent than fatigue, 61% of patients say that fatigueaffects their lives more than pain. And while most patients feel that fatigueis caused by their treatment, most physicians believe that the cancer isthe cause, which may explain why most patients (75%) are resigned to livingwith their fatigue.

In response to the survey, The Fatigue Coalition plans to develop aseries of educational and research initiatives designed to help patientsand physicians better understand the onset, duration, and progression offatigue in cancer and how to intervene successfully.

Articles in this issue

Bills Address Women's Health and Cancer Issues
Possible Evolutionary Advantage Seen in Breast Cancer Genes
Physicians Urged to Listen to Tamoxifen Users' Concerns
Neck Check Exam Aims at Early Detection
Upcoming Multicenter Study Will Compare Digital Versus Film Screen Mammography
Investigation Clears Fisher of Scientific Misconduct Charges In NSABP Studies
NCAB to Consider Mammography in Forties
Endocrinologists Issue Clinical Guidelines for Thyroid Cancer
Fatigue May Be Most Under-recognized, Undertreated Cancer-related Symptom
Hormone Replacement Therapy: Making Informed Decisions
AHCPR Issues Colorectal Cancer Screening Evidence Report
Genetic Advances Allow Early Detection of MEN Syndromes
MRI Used to Detect Local Prostate Cancer Recurrence After Prostatectomy
Proposed Budget Increase for NCI Is Below Expected Rate of Inflation
Mammography in One's 40s: Considering the Arguments
Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Advertisement

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Chris Ryan
October 17th 2025
Article

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Kristi Rosa
October 17th 2025
Article

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer

Ashling Wahner
October 17th 2025
Article

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Related Content
Advertisement

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Chris Ryan
October 17th 2025
Article

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Kristi Rosa
October 17th 2025
Article

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.


Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.


Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer

Ashling Wahner
October 17th 2025
Article

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.